RxDoctor Payments Data

Bo Jiang, MD

Cardiovascular Disease · Rocky Mount, NCNPI 1205199536

Payments from drug & device makers

$2,596in general payments, 2019–2025

Across 137 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$459
  • E.r. Squibb & Sons, L.L.C.$319
  • Johnson & Johnson$315
  • Boehringer Ingelheim$307
  • Merck$267
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$179
  • plus $751 from 12 others

What the payments were for

  • Food & beverage$2,596100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,596 in reported general payments places this provider in the 50th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$146,445
Medicare patients
441
Services billed
2,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban405$372,745
EntrestoSacubitril/Valsartan190$165,923
XareltoRivaroxaban182$134,326
JardianceEmpagliflozin87$100,276
OzempicSemaglutide19$19,248
Repatha SureclickEvolocumab21$14,544
FarxigaDapagliflozin Propanediol18$12,862
Repatha SyringeEvolocumab16$10,088
Metoprolol Succinate490$4,193
Atorvastatin Calcium328$2,801
Losartan Potassium288$2,752
Amlodipine Besylate417$2,025
Carvedilol256$1,495
Furosemide304$1,420
Lisinopril192$1,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$156$372,745405 claims
NovartisEntresto$459$165,923190 claims
Johnson & JohnsonXarelto$315$134,326182 claims
Boehringer IngelheimJardiance$307$100,27687 claims
Novo NordiskOzempic$125$19,24819 claims
AstraZenecaFarxiga$60$12,86218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →